Loading…
Apollomics, Inc. is projected to rise to $27.78 by 2027, a +47% move from its current price of $18.95. APLM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.88 | $18.93 | $20.03 | -0.13% |
| Jul 14 | $17.44 | $18.90 | $20.49 | -0.26% |
| Jul 15 | $17.10 | $18.88 | $20.83 | -0.39% |
| Jul 16 | $16.82 | $18.85 | $21.13 | -0.53% |
| Jul 17 | $16.57 | $18.83 | $21.38 | -0.66% |
| Jul 18 | $16.35 | $18.80 | $21.62 | -0.79% |
| Jul 19 | $16.15 | $18.78 | $21.83 | -0.92% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.15 | $18.78 | $21.83 | -0.92% |
| Week 2 | $15.03 | $18.60 | $23.02 | -1.83% |
| Week 3 | $14.20 | $18.43 | $23.93 | -2.73% |
| Week 4 | $13.51 | $18.26 | $24.69 | -3.62% |
| Week 5 | $12.92 | $18.10 | $25.35 | -4.51% |
| Week 6 | $12.40 | $17.93 | $25.94 | -5.38% |
| Week 7 | $11.92 | $17.77 | $26.47 | -6.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apollomics, Inc. is a clinical-stage biopharmaceutical company in Healthcare that engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
Its product portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. The company also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors.
The company was founded in 2015 and is based in Foster City, California.
Apollomics, Inc. trades under the symbol APLM. The current price is $20.16 and the market cap is $44.27M, with a rank of 4644.
The forecast presents a long-run price outlook with the average price rising from $20.16 in 2026 to $142.82 by 2050, and ROI increasing to 608.4% by 2050, indicating substantial upside potential in the long term.
The 30-day technical snapshot shows a range of $12.88 to $31.55, and volatility is noted at 100% annualized. Current indicators place the stock in a bullish technical posture, with RSI around 60, and moving averages and support/resistance levels shaping near-term dynamics.
A major floor 50.6% below — a decisive break under it would weaken the trend.
The nearest floor, 27.7% below — buyers have tended to step in here.
The nearest ceiling, 20.5% above — a clean break opens room to run.
A major ceiling 45.8% above — clearing it would confirm fresh momentum.
Key APLM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APLM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.03 | Sell | $19.13 | Sell |
| MA 10 | $19.79 | Sell | $19.23 | Sell |
| MA 20 | $18.55 | Buy | $18.52 | Buy |
| MA 50 | $16.08 | Buy | $17.09 | Buy |
| MA 100 | $16.72 | Buy | $16.71 | Buy |
| MA 200 | $17.74 | Buy | $16.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.05 | Neutral |
| Stoch RSI (14) | 2.49 | Buy |
| CCI (20) | 11.20 | Neutral |
| Williams %R (14) | -96.28 | Info |
| MACD (12,26,9) | -0.24 | Sell |
| ROC (12) | -5.67 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 3.72 | Buy |
| TRIX (15) | 1.25 | Buy |
| Awesome (5,34) | 2.32 | Buy |
| Ultimate (7,14,28) | 31.48 | Neutral |
| Momentum (10) | -3.05 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 18.56 | Buy |
| ADX (14) | 18.25 | Neutral |
| ATR (14) | 0.72 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. This suggests solid near-term momentum.
The price is trading above both the SMA50 and SMA200, which stand at $15.36 and $17.65 respectively, signaling near-term strength relative to the mid- and long-term averages.
Key near-term levels include a support at $13.52 and a resistance at $22.83. The 30-day price range spans from $12.88 to $31.55, underscoring notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.85 | $18.95 | $22.51 | 0% | Neutral | |
| $20.16 | $27.78 | $41.39 | +47% | Bullish | |
| $23.23 | $34.02 | $54.02 | +80% | Bullish | |
| $19.51 | $30.10 | $50.18 | +59% | Bullish | |
| $20.87 | $33.76 | $58.59 | +78% | Bullish | |
| $19.07 | $32.24 | $57.92 | +70% | Bullish | |
| $17.21 | $30.34 | $56.21 | +60% | Bullish | |
| $21.25 | $39.02 | $74.30 | +106% | Bullish | |
| $24.40 | $46.60 | $90.97 | +146% | Bullish | |
| $28.28 | $56.15 | $112.15 | +196% | Bullish | |
| $29.09 | $64.64 | $141.90 | +241% | Bullish | |
| $55.06 | $122.36 | $281.43 | +546% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.85 | $18.95 | $23.10 | +0.00% |
| August 2026 | $14.22 | $17.23 | $21.73 | -9.10% |
| September 2026 | $13.68 | $16.80 | $21.64 | -2.45% |
| October 2026 | $14.30 | $17.79 | $23.31 | +5.85% |
| November 2026 | $13.80 | $17.34 | $23.05 | -2.54% |
| December 2026 | $13.17 | $16.71 | $22.51 | -3.62% |
Click any year to see its month-by-month APLM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APLM price prediction for 2026 points to an average of $18.95 (low $12.85, high $22.51) — a potential gain of 0% on today's $18.95. A consolidation phase looks the most probable path here.
In 2027, APLM is projected to trade between $20.16 and $41.39, averaging $27.78 — a potential gain of +47% from today's $18.95. That is up +47% on the projected 2026 average. Momentum favours further upside here.
Apollomics, Inc.'s 2028 outlook centres on $34.02, within a $23.23 to $54.02 range. That is up +22% on the projected 2027 average. That marks a +80% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, APLM could reach as high as $50.18, with a base case around $30.10 and support toward $19.51 — roughly +59% from $18.95. Momentum favours further upside here.
Expect APLM to range from $20.87 to $58.59 through 2030. The $33.76 average target implies a +78% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The APLM price prediction for 2031 points to an average of $32.24 (low $19.07, high $57.92) — a potential gain of +70% on today's $18.95. Momentum favours further upside here.
In 2032, APLM is projected to trade between $17.21 and $56.21, averaging $30.34 — a potential gain of +60% from today's $18.95. That is -6% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Apollomics, Inc.'s 2033 outlook centres on $39.02, within a $21.25 to $74.30 range. That is up +29% on the projected 2032 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2034, APLM could reach as high as $90.97, with a base case around $46.60 and support toward $24.40 — roughly +146% from $18.95. Buyers look set to stay in control over this stretch.
Expect APLM to range from $28.28 to $112.15 through 2035. The $56.15 average target implies a +196% move from current prices. That is up +20% on the projected 2034 average. Momentum favours further upside here.
The APLM price prediction for 2040 points to an average of $64.64 (low $29.09, high $141.90) — a potential gain of +241% on today's $18.95. Buyers look set to stay in control over this stretch.
In 2050, APLM is projected to trade between $55.06 and $281.43, averaging $122.36 — a potential gain of +546% from today's $18.95. That is up +89% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in APLM today (≈ 52.770449 APLM) could be worth
$6,457.05
+$5,457.05 (+546%) by 2050 · US Dollar
Based on the average projected APLM price of $122.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APLMwould be worth at today's price.
$1,000 invested in APLM on Jul 10, 2025 (≈ 175.438602 APLM) would be worth
$3,324.56
+$2,324.56 (+232.5%) today · 3.32× · US Dollar
Based on a APLM entry price of $5.7 vs. today's $18.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.56 | $968.81 | -3.1% |
| 1 month ago | $13.79 | $1,374.18 | +37.4% |
| 3 months ago | $13.6 | $1,393.38 | +39.3% |
| 6 months ago | $21.75 | $871.26 | -12.9% |
| 1 year ago | $5.7 | $3,324.56 | +232.5% |
| All time (4.6y) ago | $990 | $19.14 | -98.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APLM forecast.
Our base-case forecast reaches $38.00 around 2033.
Implied market cap at $38.00: $83.45M
The multi-year forecast shows a bullish trajectory across the horizon, with 2026 labeled NEUTRAL and 2027 through 2050 labeled BULLISH.
From 2027 onward, the average price trends higher, with 2027 at $30.86 and 2030 at $37.49, while ROI climbs from 53.1% in 2027 to 85.9% in 2030. The longer horizon shows substantial upside, with 2040 averaging $72.63 and ROI 260.3, and 2050 averaging $142.82 with ROI 608.4.
Within the forecast, some years show lower minimums (e.g., 2029 min $21.09, 2031 min $20.70, 2032 min $19.02) alongside higher maximums (e.g., 2033 max $85.29, 2034 max $101.99, 2035 max $126.87). These figures reflect volatility and uncertainty in long-run projections, but the longer-term outlook remains bullish.
Tap a question to reveal the answer.
2026 min $12.85; avg $20.16; max $24.86; ROI 0; sentiment NEUTRAL. 2027 min $22.35; avg $30.86; max $46.07; ROI 53.1; sentiment BULLISH. 2030 min $23.15; avg $37.49; max $65.12; ROI 85.9; sentiment BULLISH.
The forecast shows NEUTRAL in 2026 and BULLISH from 2027 onward, with higher average prices and ROI through 2050. These numbers are estimates and not financial advice.
Yes. The max prices in the forecast reach $101.99 in 2034, $126.87 in 2035, $159.51 in 2040, and $328.48 in 2050.
The current price is $20.16.
The 30-day price range is $12.88 to $31.55.
Apollomics, Inc. Community Discussion
0Share your Apollomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.